Austhera BioSciences

Austhera BioSciences was a U.S.-based clinical-stage pharmaceutical development company headquartered in Georgetown, Texas. The company focused on reformulating poorly absorbed drugs and applying the KinetiSol drug delivery and formulation platform to create development-stage assets for oncology, rare disease, and other specialty indications. Publicly available descriptions indicate a portfolio that included abiraterone for hormone-sensitive prostate cancer, deferasirox for iron overload, rivaroxaban for antiphospholipid syndrome, nintedanib for lung disease, and protrexed for cancer. Austhera was closely associated with DisperSol Technologies, which described Austhera as its wholly owned subsidiary. More recent third-party company databases characterize Austhera as inactive or deadpooled, and there is no clear evidence that it remains an operating standalone biotech company as of 2026.